1. Home
  2. VOXR vs CCCC Comparison

VOXR vs CCCC Comparison

Compare VOXR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

HOLD

Current Price

$5.04

Market Cap

293.7M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.03

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOXR
CCCC
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.7M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VOXR
CCCC
Price
$5.04
$2.03
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.25
AVG Volume (30 Days)
644.7K
1.5M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
1.01%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,158,304.00
$30,108,000.00
Revenue This Year
$43.78
N/A
Revenue Next Year
$89.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.06
N/A
52 Week Low
$2.21
$1.09
52 Week High
$5.54
$4.44

Technical Indicators

Market Signals
Indicator
VOXR
CCCC
Relative Strength Index (RSI) 57.21 34.55
Support Level $5.15 $2.50
Resistance Level $5.39 $2.69
Average True Range (ATR) 0.25 0.19
MACD -0.03 -0.07
Stochastic Oscillator 45.90 5.92

Price Performance

Historical Comparison
VOXR
CCCC

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: